0 CHECKOUT

Gliosarcoma - Pipeline Review, H1 2015

  • ID: 3330526
  • June 2015
  • 62 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Celgene Corporation
  • Merck & Co., Inc.
  • Sanofi
  • MORE

Gliosarcoma - Pipeline Review, H1 2015

Summary

This, ‘Gliosarcoma - Pipeline Review, H1 2015’, provides an overview of the Gliosarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Celgene Corporation
  • Merck & Co., Inc.
  • Sanofi
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Gliosarcoma Overview
Therapeutics Development
Pipeline Products for Gliosarcoma - Overview
Pipeline Products for Gliosarcoma - Comparative Analysis
Gliosarcoma - Therapeutics under Development by Companies
Gliosarcoma - Therapeutics under Investigation by Universities/Institutes
Gliosarcoma - Pipeline Products Glance
Clinical Stage Products
Gliosarcoma - Products under Development by Companies
Gliosarcoma - Products under Investigation by Universities/Institutes
Gliosarcoma - Companies Involved in Therapeutics Development
Amgen Inc.
Burzynski Research Institute, Inc.
Celgene Corporation
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
NewLink Genetics Corporation
Sanofi
Gliosarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alisertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antineoplaston Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-122 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DNX-2401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
indoximod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lonafarnib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oncolytic Virus to Target IL-12 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plerixafor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rilotumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SGT-53 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Glioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gliosarcoma - Recent Pipeline Updates
Gliosarcoma - Dormant Projects
Gliosarcoma - Product Development Milestones
Featured News & Press Releases
Nov 26, 2013: Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Gliosarcoma, H1 2015
Number of Products under Development for Gliosarcoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Gliosarcoma - Pipeline by Amgen Inc., H1 2015
Gliosarcoma - Pipeline by Burzynski Research Institute, Inc., H1 2015
Gliosarcoma - Pipeline by Celgene Corporation, H1 2015
Gliosarcoma - Pipeline by Merck & Co., Inc., H1 2015
Gliosarcoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Gliosarcoma - Pipeline by NewLink Genetics Corporation, H1 2015
Gliosarcoma - Pipeline by Sanofi, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Gliosarcoma Therapeutics - Recent Pipeline Updates, H1 2015
Gliosarcoma - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Gliosarcoma, H1 2015
Number of Products under Development for Gliosarcoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Amgen Inc.
Burzynski Research Institute, Inc.
Celgene Corporation
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
NewLink Genetics Corporation
Sanofi

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Novartis AG
  • Qiagen N.V.
  • Elekta AB
  • Roche Diagnostics Ltd.
  • Bristol-Myers Squibb
  • Genentech, Inc.